Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects
This article was originally published in The Pink Sheet Daily
The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.
You may also be interested in...
Deal Snapshot: Building on a 2021 tie-up between Takeda and the Paragon start-up, Evozyne will seek novel protein sequences for inclusion in gene therapies for rare disease indications.
The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.